AU2001288968A1 - Antisense modulation of btak expression - Google Patents
Antisense modulation of btak expressionInfo
- Publication number
- AU2001288968A1 AU2001288968A1 AU2001288968A AU8896801A AU2001288968A1 AU 2001288968 A1 AU2001288968 A1 AU 2001288968A1 AU 2001288968 A AU2001288968 A AU 2001288968A AU 8896801 A AU8896801 A AU 8896801A AU 2001288968 A1 AU2001288968 A1 AU 2001288968A1
- Authority
- AU
- Australia
- Prior art keywords
- btak
- expression
- antisense modulation
- antisense
- modulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101150095401 AURKA gene Proteins 0.000 title 1
- 230000000692 anti-sense effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01037—Protein kinase (2.7.1.37)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09660925 | 2000-09-11 | ||
| US09/660,925 US6352858B1 (en) | 2000-09-11 | 2000-09-11 | Antisense modulation of BTAK expression |
| PCT/US2001/028231 WO2002022639A1 (en) | 2000-09-11 | 2001-09-10 | Antisense modulation of btak expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001288968A1 true AU2001288968A1 (en) | 2002-03-26 |
Family
ID=24651505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001288968A Abandoned AU2001288968A1 (en) | 2000-09-11 | 2001-09-10 | Antisense modulation of btak expression |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US6352858B1 (en) |
| AU (1) | AU2001288968A1 (en) |
| WO (1) | WO2002022639A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003020739A2 (en) * | 2001-09-04 | 2003-03-13 | Exiqon A/S | Novel lna compositions and uses thereof |
| US20040077569A1 (en) * | 2002-10-16 | 2004-04-22 | Isis Pharmaceuticals Inc. | Antisense modulation of Notch (Drosophila) homolog 4 expression |
| US7572914B2 (en) * | 2003-12-19 | 2009-08-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EP1763524A1 (en) * | 2004-04-23 | 2007-03-21 | Takeda San Diego, Inc. | Indole derivatives and use thereof as kinase inhibitors |
| WO2006031273A2 (en) * | 2004-06-18 | 2006-03-23 | Cytokinetics, Inc. | Cellular phenotype |
| US7550598B2 (en) * | 2004-08-18 | 2009-06-23 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EP1812439B2 (en) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US20070082327A1 (en) * | 2005-09-09 | 2007-04-12 | Cytokinetics, Inc. A Delaware Corporation | Cellular phenotype |
| US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| JP2010505961A (en) * | 2006-10-09 | 2010-02-25 | タケダ サン ディエゴ インコーポレイテッド | Kinase inhibitor |
| BRPI0719883A2 (en) | 2006-10-09 | 2015-05-05 | Takeda Pharmaceutical | Kinase Inhibitors |
| EP2169077A1 (en) * | 2008-09-19 | 2010-03-31 | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg | Methods and compositions for diagnosing an adenocarcinoma |
| WO2012066092A1 (en) * | 2010-11-19 | 2012-05-24 | Santaris Pharma A/S | Compounds for the modulation of aurora kinase a expression |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| IL124728A (en) | 1995-12-18 | 2007-06-03 | Sugen Inc | Aurora-1 and aurora-2 proteins |
-
2000
- 2000-09-11 US US09/660,925 patent/US6352858B1/en not_active Expired - Lifetime
-
2001
- 2001-09-10 WO PCT/US2001/028231 patent/WO2002022639A1/en not_active Ceased
- 2001-09-10 AU AU2001288968A patent/AU2001288968A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US6352858B1 (en) | 2002-03-05 |
| WO2002022639A1 (en) | 2002-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001289085A1 (en) | Antisense modulation of flip-c expression | |
| AU2001229493A1 (en) | Antisense modulation of mekk2 expression | |
| AU2212600A (en) | Antisense modulation of g-alpha-i1 expression | |
| AU6296099A (en) | Antisense modulation of g-alpha-12 expression | |
| AU2002309819A1 (en) | Antisense modulation of PTP1B expression | |
| AU2001277054A1 (en) | Antisense modulation of lysophospholipase i expression | |
| AU2001289046A1 (en) | Antisense modulation of her-2 expression | |
| AU2001294926A1 (en) | Antisense modulation of smad6 expression | |
| AU2001278077A1 (en) | Antisense modulation of ptp1b expression | |
| AU2001229447A1 (en) | Antisense modulation of smad7 expression | |
| AU2001261808A1 (en) | Antisense modulation of pten expression | |
| AU2001263171A1 (en) | Antisense modulation of tert expression | |
| AU2001239971A1 (en) | Antisense modulation of parp expression | |
| AU2002350228A1 (en) | Antisense modulation of myd88 expression | |
| AU6115400A (en) | Antisense modulation of mekk5 expression | |
| AU2001227847A1 (en) | Antisense modulation of pepck-cytosolic expression | |
| AU2001288968A1 (en) | Antisense modulation of btak expression | |
| AU2002366788A1 (en) | Antisense modulation of ship-1 expression | |
| AU2002318139A1 (en) | Antisense modulation of src-c expression | |
| AU2002230869A1 (en) | Antisense modulation of hepsin expression | |
| AU2209000A (en) | Antisense modulation of pepck-mitochondrial expression | |
| AU2002226064A1 (en) | Antisense modulation of talin expression | |
| AU5486700A (en) | Antisense modulation of g-alpha-s1 expression | |
| AU2002357102A1 (en) | Antisense modulation of cd36l1 expression | |
| AU2001287136A1 (en) | Antisense modulation of glioma-associated oncogene-1 expression |